Diffuse large B-cell lymphoma: examining evolving patterns in mortality, incidence, and demographics.

Area of Science:

• Hematology
• Oncology
• Epidemiology

Background:

• Diffuse large B-cell lymphoma (DLBCL) is the most prevalent and aggressive non-Hodgkin lymphoma subtype.
• DLBCL is characterized by significant heterogeneity, impacting patient outcomes and treatment strategies.

Purpose of the Study:

• To analyze recent trends in DLBCL hospitalizations, inpatient mortality, and associated costs.
• To identify demographic and clinical factors influencing DLBCL incidence and outcomes.

Main Methods:

• Retrospective cohort study utilizing the Nationwide Inpatient Sample (NIS) database (2016-2020).
• Analysis included DLBCL hospitalizations, discharges, and outcomes, adjusted for various demographic and hospital factors.
• Multivariable logistic regression was employed to assess trends and risk factors.

Main Results:

• Hospitalizations for DLBCL increased from 2016 to 2020, with a mean age at diagnosis of 65.
• Increasing trends observed in male and Hispanic populations, alongside rising comorbidities like obesity and hypertension.
• Inpatient mortality showed fluctuations, while hospital charges significantly increased; discharge patterns shifted towards home health and short-term care.

Conclusions:

• White males and individuals around age 65 represent key demographics for DLBCL.
• A notable increase in DLBCL incidence among the Hispanic population warrants further investigation.
• Significant disparities in DLBCL incidence and survival exist across ethnic and demographic groups, necessitating targeted interventions and equitable healthcare access.